Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Bevacizumab (added to chemotherapy)
Treatment for Colon and rectum cancer
Typical Dosage: 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks (with chemotherapy)
Effectiveness
75%
Safety Score
35%
Clinical Trials
2
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks (with chemotherapy)
Time to Effect
1-3 months
Treatment Duration
Until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$110,000
Monitoring:$17,000
Side Effect Mgmt:$15,000
Total Annual:$142,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$236,667
Cost per Remission
$2,840,000
Comparison vs FOLFOX
Cost Difference
+$97,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Bevacizumab (added to chemotherapy) in Colon and rectum cancer
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
NCT01814501COMPLETEDPHASE2
16 participants
INTERVENTIONAL
Columbus, United States +1 more
Started: Feb 1, 2013
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
NCT00462501COMPLETEDNA
35 participants
INTERVENTIONAL
New York, United States
Started: Mar 1, 2007